{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Advanced+Malignant+Solid+Neoplasm", "query": { "condition": "Recurrent Advanced Malignant Solid Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 126, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Advanced+Malignant+Solid+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T11:59:00.257Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03507452", "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma", "Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma", "Advanced Recurrent Serous Ovarian Cancer", "Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)" ], "interventions": [ { "name": "BAY2287411", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-06-13", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03507452" }, { "nct_id": "NCT06952010", "title": "A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Metastatic Solid Tumor", "Immune Sensitive Tumor" ], "interventions": [ { "name": "XB628", "type": "BIOLOGICAL" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2025-05-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952010" }, { "nct_id": "NCT04795713", "title": "Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "MT-6402", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2021-05-27", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04795713" }, { "nct_id": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Cutaneous Melanoma", "Locally Advanced Mucosal Melanoma", "Metastatic Acral Melanoma", "Metastatic Conjunctival Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Mucosal Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma", "Recurrent HER2-Negative Breast Carcinoma", "Recurrent Hormone Receptor-Positive Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Mucosal Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-06-09", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098210" }, { "nct_id": "NCT06320405", "title": "Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Axatilimab", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2024-05-21", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06320405" }, { "nct_id": "NCT05798611", "title": "Study of ART0380 in Patients With Biologically Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Recurrent Endometrial Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "ART0380", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artios Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-09-06", "completion_date": "2025-05-27", "has_results": false, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 8, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798611" }, { "nct_id": "NCT05039801", "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Clear Cell Adenocarcinoma", "Chondrosarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Melanoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Stage III Ovarian Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Glutaminase-1 Inhibitor IACS-6274", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-30", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039801" }, { "nct_id": "NCT04541225", "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-12-08", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 12, "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541225" }, { "nct_id": "NCT05058339", "title": "Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Malignant Solid Neoplasm", "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Recurrent Hematologic Malignancy", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 223, "start_date": "2021-04-27", "completion_date": "2024-09-06", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05058339" }, { "nct_id": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Differentiated Thyroid Gland Carcinoma", "Advanced Head and Neck Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Kaposi Sarcoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Prostate Carcinoma", "Advanced Renal Cell Carcinoma", "Advanced Thyroid Gland Medullary Carcinoma", "Advanced Triple-Negative Breast Carcinoma", "Advanced Urothelial Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "HIV Infection", "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic Head and Neck Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Kaposi Sarcoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Thyroid Gland Medullary Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Kaposi Sarcoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Medullary Carcinoma", "Recurrent Triple-Negative Breast Carcinoma", "Recurrent Urothelial Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2021-11-22", "completion_date": "2027-02-06", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-25T11:59:00.257Z", "location_count": 3, "location_summary": "Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514484" } ] }